Schizophrenia Clinical Trial
— DMTinSchizoOfficial title:
The Effect of Dance and Movement Therapy as a Group Work Technique on Negative Symptoms and Disability in Patients With Schizophrenia
Verified date | May 2023 |
Source | Amasya University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms. While drug therapy in schizophrenia targets positive symptoms; psychotherapies are needed in the treatment of negative symptoms. It is seen that especially art therapies such as occupational and music support recovery and rehabilitation. In addition, it is stated that dance and movement therapy is effective in ensuring social participation of patients. There are a limited number of studies demonstrating the effect of dance and movement therapy on schizophrenia patients. Aim: This project was planned to examine the effects of dance and movement therapy techniques to be applied to patients with schizophrenia on patients' negative symptoms and disability. Method: In this project, which was planned in a repetitive measure design with a pretest-posttest control group, dance and movement therapy techniques, consisting of 12 sessions in total, will be applied to schizophrenic patients in a Community Mental Health Center once a week. Negative symptoms and disability levels will be determined before, after and a month after the application. The findings obtained as a result of these three follow-ups will be evaluated. Project Outputs: Reduction of negative symptoms and disability will enable schizophrenic patients to become individuals who can express themselves better in their family and society and have an increased quality of life. It is thought that these gains will increase patients' compliance with treatment, prevent recurrent symptoms and reduce hospitalizations. The results will also constitute a scientific source for the studies to be carried out in the field.
Status | Completed |
Enrollment | 30 |
Est. completion date | February 15, 2023 |
Est. primary completion date | December 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - have been diagnosed with schizophrenia for at least two years - not have been hospitalized in the past 3 months Exclusion Criteria: - have a therapy/psychoeducation program that they attend regularly - have a known physical or neurological disease - having just started the Community Mental Health Center |
Country | Name | City | State |
---|---|---|---|
Turkey | Amasya Üniversitesi Sabuncuoglu Serefeddin Egitim Ve Arastirma Hastanesi | Amasya |
Lead Sponsor | Collaborator |
---|---|
Amasya University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Personal Information Form | The questionnaire form prepared by the project team consists of 10 questions in total, including the socio-demographic characteristics (age, gender, marital status, education level, employment status, income level, cohabitants) of the patients and their disease-related characteristics (age of onset of disease, duration of disease (years), number of hospitalizations). | 2 weeks | |
Primary | The Scale for the Assessment of Negative Symptoms (SANS) | Scale; It consists of five parts, including flattening or blunting in affect, alogy, decreased energy and desire, lack of pleasure and social withdrawal, attention, and a total of 24 items. Scale items 0=none; 1=doubtful; 2=light; 3=medium; 4=pronounced; It is scored as 5=severe. The negative symptoms rating scale is a type of scale that the interviewer evaluates. The filling of the scale is based on the interview with the patient, the observations during the interview and the information received from the people around the patient. Cronbach's alpha for the whole scale is 0.94.
Values that can be taken from the Scale for the Assessment of Negative Symptoms (SANS); minimum=0, maximum=120 points. It shows that as the score increases, the severity of negative symptoms increases. |
6 months | |
Primary | Disability Evaluation Schedule (WHO-DAS-II) | Disability Assessment Chart is a 36-item scale. This tool tries to determine how much difficulty an individual with schizophrenia has while performing certain activities and consists of 6 areas that include activities that are considered important in many cultures. These are grouped under the headings of understanding and communicating, moving and moving from place to place, self-care, human relations, life activities, participation in social life. In questions about all these areas, it is asked how much difficulty the person has had during that activity in the last month, and the answers received as not at all, mild, moderate, very much, excessively/not at all are scored between 1-5. It is applied by the interviewer in approximately 20 minutes. Cronbach's alpha for the whole scale is 0.92.
Values that can be taken from the Disability Evaluation Schedule (WHO-DAS-II); minimum=0, maximum=100 points. It shows that as the score increases, the severity of disability increases. |
6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |